Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).

Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy, fibrosis, autoimmune, cardiovascular and metabolic diseases.